However, studies using several tumor models have shown that CD4+ T cells can efficiently eliminate major histocompatibility complex (MHC) class II expressing tumor cells [1, 2] as well as tumors lacking MHC class II molecules [3–5], demonstrating a direct role of CD4+ T cells in tumor rejection. Here, CD4 is linked to neoplasm.